Status:
COMPLETED
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
VHL Alliance
Conditions:
Von Hippel-Lindau Disease
Hemangioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors. The VHL protein is not functional in the different ...
Eligibility Criteria
Inclusion
- clinically or genetically proven VHLD
- at least 1 measurable, VHL associated lesion in the CNS
- routine MRI of the CNS ≤ 6 weeks before inclusion
- routine CT or MRI of upper abdomen ≤ 3 months before inclusion or planned ≤ 3 months after 89Zr-bevacizumab PET scan
- age ≥ 18 years
- written informed consent must be given according to good clinical practice (GCP), and local regulations
Exclusion
- pregnancy
- any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol, those conditions should be discussed with the patient before registration in the trial
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00970970
Start Date
September 1 2009
End Date
November 1 2012
Last Update
May 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9700 RB